TRANSGENE: First Half-Year 2017 In Line With Our Objectives: All Clinical Programs Progressing And New Collaboration Agreements Signed
Published: Sep 13, 2017
STRASBOURG, France--(BUSINESS WIRE)--Regulatory News:
Seven active clinical trials:
- First patients treated in four combination trials assessing TG4010 (lung cancer) or Pexa-Vec (liver cancer and other solid tumors)
Two collaboration agreements signed with:
- Bristol-Myers Squibb, for a combination clinical trial of TG4010 (1st-line treatment of lung cancer)
- Servier, for a scientific collaboration to improve the production process for allogenic CAR-T cells
- Cash and cash equivalents as of June 30, 2017: €43.9 million, financial visibility confirmed to the end of 2018
Transgene (Paris:TNG), a biotechnology company focused on designing and developing viral-based immune-targeted therapies, today announced its financial results for the six-month period ended June 30, 2017, and reviews the progress of it products portfolio since the beginning of the year.
Philippe Archinard, Chairman and Chief Executive Officer of Transgene said: “Transgene is continuing to successfully execute its strategy. We are making progress with our clinical development plans with seven active trials as of today, and in parallel we are continuing to advance our cutting edge research program.
Four of the clinical trials are aiming to confirm the potential of TG4010 or Pexa-Vec in combination with immune checkpoint inhibitors (ICIs), including in two high unmet need indications, lung and liver cancer.
We have signed two collaborations, one with Bristol-Myers Squibb (BMS) covering a combination study with TG4010 in the first-line treatment of lung cancer, and one with Servier for the design of an optimized production process of allogenic CAR-T cells using our viral vectorization technology. These new deals build on our existing collaborations with BMS for TG4010 in the 2nd-line treatment of lung cancer and with Merck KGaA/Pfizer for TG4001 in head and neck cancers. We believe these agreements provide strong validation of the potential of our immunotherapy approach.
With our current funding, Transgene is well placed to progress its programs through to the end of 2018. We will continue to focus all of our energy to advance our multiple clinical trials and to seize the development opportunities that they could create for Transgene.”